Intrua Financial LLC Decreases Stake in Johnson & Johnson $JNJ

Intrua Financial LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 15.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 16,101 shares of the company’s stock after selling 2,862 shares during the quarter. Intrua Financial LLC’s holdings in Johnson & Johnson were worth $2,459,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after purchasing an additional 1,170,120 shares during the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.1% during the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after buying an additional 1,225,676 shares during the period. Northern Trust Corp grew its position in Johnson & Johnson by 0.4% during the first quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares during the period. Bank of New York Mellon Corp increased its holdings in Johnson & Johnson by 2.7% during the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after buying an additional 620,039 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Johnson & Johnson by 3.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock worth $3,133,602,000 after acquiring an additional 712,181 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. UBS Group upped their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Citigroup raised their target price on Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $200.52.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $195.19 on Friday. The business’s fifty day moving average is $185.46 and its 200 day moving average is $169.66. The firm has a market cap of $470.27 billion, a price-to-earnings ratio of 18.84, a PEG ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $196.00.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $24.02 billion during the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.